Literature DB >> 29085513

Prognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma.

Liting Zhong1, Chunming Li2, Yunyan Ren3, Dehua Wu1.   

Abstract

The aim of the present study was to investigate the association between positron emission tomography (PET) parameters and peripheral inflammatory markers, and assess their prognostic value in nasopharyngeal carcinoma (NPC). A total of 121 patients with non-disseminated NPC were recruited. Pretreatment maximum standardized uptake values (SUVmax) of PET and peripheral inflammatory factors (leukocyte, neutrophil and monocyte counts) were recorded. Kaplan-Meier and multivariate analyses were used to identify predictors for progression-free survival (PFS), overall survival (OS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS). The results of the present study revealed that SUVmax at the primary tumor was positively correlated with leukocytes (P=0.025), neutrophils (P=0.009) and monocytes (P=0.043). SUVmax at regional lymph nodes (SUVmax-N) was significantly associated with monocytes (P=0.024). Kaplan-Meier analysis demonstrated that SUVmax-N (>10.15) significantly predicted PFS (P=0.004) and DMFS (P=0.003). In addition, neutrophils (>5.18) were significantly associated with PFS (P=0.001), DMFS (P=0.013) and LRFS (P<0.001). Multivariate analysis revealed that SUVmax-N and neutrophils retained independent prognostic significance for PFS (SUVmax-N, P=0.026; and neutrophils, P=0.033) and DMFS (SUVmax-N, P=0.026; and neutrophils, P=0.032). Furthermore, patients with SUVmax-N ≤10.15 and neutrophils ≤5.18 had significantly improved prognosis in PFS (96.4 vs. 58.5%, P<0.001), OS (95.7 vs. 81.1%, P=0.044), DMFS (96.4 vs. 67.0%, P<0.001) and LRFS (100 vs. 90.2%, P=0.036) compared with those with SUVmax-N >10.15 or neutrophils >5.18. In conclusion, SUVmax may be significantly associated with cancer-associated inflammation. SUVmax-N and neutrophils were independent prognostic indicators for PFS and DMFS. Combined assessment of SUVmax-N and neutrophils may lead to refinement of risk stratification in NPC.

Entities:  

Keywords:  inflammation; maximum standardized uptake values; nasopharyngeal carcinoma; prognostic value

Year:  2017        PMID: 29085513      PMCID: PMC5649619          DOI: 10.3892/ol.2017.6816

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

1.  Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma.

Authors:  Jian-Rong He; Guo-Ping Shen; Ze-Fang Ren; Han Qin; Cui Cui; Ying Zhang; Yi-Xin Zeng; Wei-Hua Jia
Journal:  Head Neck       Date:  2012-02-09       Impact factor: 3.147

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Biomarkers in cancer staging, prognosis and treatment selection.

Authors:  Joseph A Ludwig; John N Weinstein
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

4.  Molecular imaging in cancer.

Authors:  Ralph Weissleder
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

5.  Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.

Authors:  Yohei Imamura; Koichi Azuma; Seiji Kurata; Satoshi Hattori; Tetsuro Sasada; Takashi Kinoshita; Masaki Okamoto; Tomotaka Kawayama; Hayato Kaida; Masatoshi Ishibashi; Hisamichi Aizawa
Journal:  Lung Cancer       Date:  2010-04-28       Impact factor: 5.705

6.  Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection.

Authors:  Haruo Inokuchi; Takeshi Kodaira; Hiroyuki Tachibana; Tatsuya Nakamura; Natsuo Tomita; Rie Nakahara; Akinori Takada; Nobutaka Mizoguchi; Tsuneo Tamaki; Nobukazu Fuwa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-29       Impact factor: 7.038

7.  FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models.

Authors:  T Mochizuki; E Tsukamoto; Y Kuge; K Kanegae; S Zhao; K Hikosaka; M Hosokawa; M Kohanawa; N Tamaki
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

8.  Positron emission tomography-computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up.

Authors:  WeiWei Xiao; AnAn Xu; Fei Han; XiaoPing Lin; LiXia Lu; GuanZhu Shen; ShaoMin Huang; Wei Fan; XiaoWu Deng; Chong Zhao
Journal:  Oral Oncol       Date:  2015-02-02       Impact factor: 5.337

Review 9.  FDG PET/CT in infection and inflammation--current and emerging clinical applications.

Authors:  S Vaidyanathan; C N Patel; A F Scarsbrook; F U Chowdhury
Journal:  Clin Radiol       Date:  2015-04-25       Impact factor: 2.350

10.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

Authors:  C Fondevila; J P Metges; J Fuster; J J Grau; A Palacín; A Castells; A Volant; M Pera
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  2 in total

1.  Radiomics Analysis of PET and CT Components of PET/CT Imaging Integrated with Clinical Parameters: Application to Prognosis for Nasopharyngeal Carcinoma.

Authors:  Wenbing Lv; Qingyu Yuan; Quanshi Wang; Jianhua Ma; Qianjin Feng; Wufan Chen; Arman Rahmim; Lijun Lu
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 2.  Radiomics in Nasopharyngeal Carcinoma.

Authors:  Wenyue Duan; Bingdi Xiong; Ting Tian; Xinyun Zou; Zhennan He; Ling Zhang
Journal:  Clin Med Insights Oncol       Date:  2022-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.